Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2013
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics
This filing reports a specific capital raise transaction rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow from operations). The filing text does not provide a clear value for operating results, margins, or existing debt levels.
| Metric | Value |
|---|---|
| Aggregate Purchase Price | Approximately $3.65 million |
| Common Shares Sold | 1,158,730 |
| Price Per Share | $3.15 |
| Warrants Issued | 869,047 |
| Warrant Exercise Price | $3.15 |
| Warrant Expiration | Five years from issuance |
Material Changes
The primary material change is the execution of a Securities Purchase Agreement on May 9, 2013, authorizing the sale of common stock and warrants to investors. The closing of this transaction is expected to occur on May 13, 2013. This represents a dilution of existing shareholders through the issuance of new equity and warrants.
Guidance, Outlook, and Risks
Transaction Terms: The offering is made pursuant to the exemption provided by Section 4(2) of the Securities Act of 1933 and Regulation D. Warrants may be exercised for cash or via a cashless exercise if the market price exceeds the exercise price.
Risks and Contingencies: The agreement includes customary representations, warranties, and covenants. These were made solely for the benefit of the parties to the agreement and are subject to specific limitations. The filing does not contain forward-looking guidance on future revenue or earnings.
Investor Verification Checklist
- Verify the final closing date of the private placement (expected May 13, 2013).
- Confirm the identity of the investors listed in Schedule A of the Purchase Agreement.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and limitations.
- Assess the impact of the 1,158,730 new shares and 869,047 warrants on existing shareholder dilution.
- Monitor subsequent filings for the actual receipt of the approximately $3.65 million in proceeds.